Testing a new medication for lymphoma that hasn't responded to prior treatments

Plain-English translation of NCT07114367 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called Poseltinib for patients with non-Hodgkin's lymphoma that has returned or stopped responding to previous treatments. Researchers are trying to find the right dose of the medication that works best while being safe and tolerable. You would be among the first patients to receive this treatment.

Many patients with certain types of non-Hodgkin's lymphoma run out of treatment options after their cancer stops responding to standard therapies. This trial is exploring whether this new medication could offer hope for patients who have already tried multiple other treatments.

Do you qualify?

You likely qualify if…

you are between 19 and 80 years old
you have been diagnosed with follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma confirmed by biopsy
your lymphoma has returned or stopped responding to treatment after you've received at least two prior treatment regimens
you have measurable disease that can be tracked on imaging
you are in good enough overall health to participate (ECOG performance status of 2 or better)
you have adequate organ function based on blood tests and other assessments

You likely don't qualify if…

you have already been treated with Poseltinib or other BTK inhibitor medications like ibrutinib, acalabrutinib, or zanubrutinib
you stopped a BTK inhibitor because the disease progressed while you were on it (though you may be eligible if you stopped due to side effects or other reasons)
you are unable to swallow pills or take oral medication
you have active HIV, hepatitis C, or hepatitis B infection
you are enrolled in another clinical trial or taking another investigational drug within the past 4 weeks

What participation looks like

You would take the study medication by mouth at increasing doses as the trial progresses, with the goal of finding the safest and most effective dose. You would visit the clinic regularly for blood tests, imaging scans, and check-ups to monitor how you're responding to the treatment and to watch for any side effects. The trial is small (enrolling about 9 patients total) and is designed to gather early safety and effectiveness information.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(6 sites)

South Korea

Chonnam National University Hwasun Hospital, Hwasun

Seoul National University Bundang Hospital, Seongnam

Catholic univ of Yeouido St Mary's Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul